Immutep (IMM) H1 2026 earnings summary

Executive summary

• Advanced lead product efti through pivotal Phase III TACTI-004 trial in 1L NSCLC, with robust patient recruitment and regulatory approvals in 27 countries.

• Entered strategic collaboration and licensing agreement with Dr. Reddy's for efti outside major markets, securing a USD 20m upfront payment and eligibility for up to USD 349.5m in milestones plus royalties.

• Reported strong clinical progress across multiple oncology and autoimmune disease trials, including positive data in breast cancer, soft tissue sarcoma, and autoimmune indications.

Financial highlights

• Total revenue and other income rose 6% to A$7.74m compared to the same period last year.

• Net loss after tax increased 100% year-over-year to A$44.86m, mainly due to higher R&D and IP expenses (A$46.62m, up from A$25.33m) and increased corporate expenses.

• Licensing revenue of A$4.1m recognized from Dr. Reddy's as R&D funding; interest income declined to A$1.6m from A$3.1m.

• Cash and cash equivalents plus term deposits totaled A$99.1m at period end, with a pro-forma balance of A$129.3m after Dr. Reddy's payment in January 2026.

• Net tangible assets per share fell to 6.31 cents from 11.30 cents year-over-year.

Outlook and guidance

• Anticipates key milestones in 2026, including TACTI-004 futility analysis and full enrolment, with multiple ongoing trials expected to provide catalysts.

• Focused on advancing efti toward commercialization and leveraging manufacturing and IP strengths.